

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nai-Kong V. CHEUNG
U.S. Serial No. : 10/565,484
Confirmation No. : 2140
Filed : January 17, 2006
Examiner : Eric Olson
Art Unit : 1623
For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

February 26, 2010

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with his duty of disclosure under 37 C.F.R. §1.56, Applicant would like to direct the Examiner's attention to the following references which are also listed on Form PTO/SB/08B (attached hereto as **Exhibit A**), and further attached as **Exhibits 1-10**.

The U.S. Patent listed (Reference 1) is on file at the USPTO; therefore, in accordance with 37 C.F.R. 1.98, a copy of this reference is not provided. However, the office of the Applicant's undersigned attorney may be contacted in the event that the Examiner would like a copy of this reference.

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: February 26, 2010
Examiner	: Eric Olson		
Page	: 2		

1. U.S. Patent No. 5,250,436, October 5, 1993, JAMAS et al., "Glucan Compositions and Process for Preparation Thereof"
2. Supplementary European Search Report, December 11, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, European Application No. EP 04786081 (Atty. Dkt. 639-C-PCT-EP). **(EXHIBIT 1)**
3. Canadian Office Action, January 25, 2010, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Canadian Application No. 2,434,938, Filed July 15, 2003, National Stage of PCT/US02/01276, Filed January 15, 2002. (Atty. Dkt. #639-A-PCT-CA) **(EXHIBIT 2)**
4. Chinese Rejection Decision, January 29, 2010, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Chinese Application No. 200480020356.6, Filed January 16, 2006, National Stage of PCT/US04/23099, Filed July 16, 2004. (with English translation) (Atty. Dkt. #639-C-PCT-CN) **(EXHIBIT 3)**
5. ANDOH, T., 1992, "Effects of Peravenous Administration of Lentinan and Concomitant Perendoscopic Localized Injection on Gastric Carcinoma in Elderly Patients", Nichidai Igaku Zasshi, 51(6):587-596. (abstract only) **(EXHIBIT 4)**
6. HAMURO, Junji, 2005, "Anticancer immunotherapy with perorally effective Lentinan", Cancer & Chemotherapy, 32(8):1209-1215. (abstract only) **(EXHIBIT 5)**
7. HERLYN et al., 1985, "Stimulation of monoclonal antibody-dependent macrophage-mediated cytotoxicity against human tumors by lentinan, International Journal of Immunopharmacology, 7(3):332. (abstract only) **(EXHIBIT 6)**

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : February 26, 2010
Examiner : Eric Olson
Page : 3


8. KANEKO et al., 1989, "Activity of Lentinan against Cancer and AIDS, International Journal of Immunotherapy, 5(4):203-213. **(EXHIBIT 7)**
9. SANO et al., 2002, "Antitumor Effects Induced by the Combination of TNP-470 as an Angiogenesis Inhibitor and Lentinan as a Biological Response Modifier in a Rabbit Spontaneous Liver Metastasis Model", Surgery Today, 32:503-509. **(EXHIBIT 8)**
10. SHIIO et al., 1977, "A study of the condition of additive use of immunotherapeutic agent, Lentinan, and chemotherapeutic agent, cyclophosphamide", Journal of Japan Society for Cancer Therapy, 15:436. (abstract only) **(EXHIBIT 9)**
11. TAKITA et al., 1998, "Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan", Cancer & Chemotherapy, 25(1):129-133. (abstract only) **(EXHIBIT 10)**

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : February 26, 2010
Examiner : Eric Olson
Page : 4

STATEMENT UNDER 37 CRF 1.97(e)

Applicant hereby states that the items of information contained in this Supplemental Information Disclosure Statement were first cited in a communication from a foreign patent office in a related foreign application (EP Application No. 04786081 (Atty. Dkt. 639-C-PCT-EP), Chinese Application No. 200480020356.6 (Atty. Dkt. 639-C-PCT-CN) or Canadian Application No. 2,434,938 (Atty. Dkt. 639-A-PCT-CA)) not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

If a telephone interview would be of assistance in advancing the prosecution of this application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below. No fee is deemed necessary in connection with the filing of this SIDS. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
Email: chank@kitchanlaw.com